Johnson & Johnson (JNJ, Financial) reported a notable revenue of $21.9 billion for the first quarter, surpassing analysts' expectations of $21.57 billion. The company's performance highlighted the robustness of its diverse portfolio, which played a crucial role in achieving strong operational sales growth. This outcome strengthens J&J's confidence in maintaining its guidance for 2025.
During the quarter, Johnson & Johnson continued to bolster its reputation as an innovation leader with significant advancements in its pipeline. Noteworthy progress was made with TREMFYA in inflammatory bowel disease and RYBREVANT combined with LAZCLUZE in treating non-small-cell lung cancer. Furthermore, the company introduced OTTAVA, a new robotic system for soft tissue surgery, and expanded its already strong neuroscience portfolio through the completion of the acquisition of Intra-Cellular Therapies.
These developments underscore J&J's commitment to maintaining its leadership in the healthcare sector through continuous innovation and strategic acquisitions.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 24 analysts, the average target price for Johnson & Johnson (JNJ, Financial) is $170.47 with a high estimate of $185.00 and a low estimate of $150.00. The average target implies an upside of 10.44% from the current price of $154.36. More detailed estimate data can be found on the Johnson & Johnson (JNJ) Forecast page.
Based on the consensus recommendation from 26 brokerage firms, Johnson & Johnson's (JNJ, Financial) average brokerage recommendation is currently 2.3, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Johnson & Johnson (JNJ, Financial) in one year is $187.89, suggesting a upside of 21.72% from the current price of $154.36. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Johnson & Johnson (JNJ) Summary page.
